Syndicate

Latest California Healthline Stories

KHN’s ‘What the Health?’: Sharing Vaccines With the World

The Biden administration is bucking the drug industry and backing a waiver of covid-19 vaccine patent protections to help the rest of the world vaccinate its populations. Here at home, the Food and Drug Administration wants to ban menthol flavorings for cigarettes, setting off a fight with the tobacco industry. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

Telemedicine Is a Tool — Not a Replacement for Your Doctor’s Touch

The pandemic has demonstrated that virtual medicine is great for simple visits. But many new types of telemedicine promoted by start-ups more clearly benefit providers’ and investors’ pockets, rather than yielding more convenient, high-quality and cost-effective medicine for patients.

How Newsom’s Reliance on Big Tech in Pandemic Undermines Public Health System

California Gov. Gavin Newsom has outsourced his way through the covid-19 pandemic, tasking his private-sector allies in Silicon Valley and the health care industry with fundamental public health duties such as testing, tracing and vaccination. Among the losers: the state’s weakened public health system.

In Appalachia and the Mississippi Delta, Millions Face Long Drives to Stroke Care

Across Appalachia and the Mississippi Delta, where death rates from stroke are above the national average, routing patients from rural areas to the right level of care can be an intricate jigsaw puzzle. The closest hospital might not offer the full scope of stroke treatments, but hospitals with more advanced care could be hours away.

Democrats Disagree About How to Spend Potential Prescription Drug Windfall

After a year of uncharacteristically being on the same page when it comes to health care, Democratic lawmakers are at loggerheads about what to do next. Most agree the time is ripe to tackle high drug prices. But they divide over whether to take savings from that to move to a ‘Medicare for All’ insurance system, enhance the current Medicare program or strengthen benefits under the Affordable Care Act.